HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Deals

Chiesi lays out $1.9B to bolster rare disease offerings with KalVista buyout

As Ekterly nears the one-year anniversary of its approval, Chiesi Group is making moves to acquire the rare disease med and its developer KalVista.

By FiercePharma · Apr 30, 2026 · via FiercePharma
Chiesi lays out $1.9B to bolster rare disease offerings with KalVista buyout

Image: FiercePharma

This is an aggregated industry headline. Read the full story at FiercePharma →

Tags
dealsformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
Lilly pens $2.2B pact with Bezos-backed Profluent to work on recombinase-based gene editing
DealsFierceBiotech ↗
Lilly pens $2.2B pact with Bezos-backed Profluent to work on recombinase-based gene editing
Eli Lilly’s latest attempt to strengthen its genetic medicine offering has seen the pharma team up with Proflu…
Apr 30, 2026
Chiesi Buys KalVista for $1.9B, Adding an Approved Drug and Commercial Unit
DealsBriefing
Chiesi Buys KalVista for $1.9B, Adding an Approved Drug and Commercial Unit
Chiesi has announced a $1.9B acquisition of KalVista Pharmaceuticals, continuing 2026’s brisk deal pace among …
Apr 29, 2026
Lilly Extends Oncology Buying Spree with $2.3B Ajax Therapeutics Acquisition
DealsBriefing
Lilly Extends Oncology Buying Spree with $2.3B Ajax Therapeutics Acquisition
Lilly’s $2.3 billion move for Ajax Therapeutics centers on a Type II JAK2 inhibitor it helped incubate, aiming…
Apr 29, 2026